The recent surge of DNA sequence information resulting from deciphering the human genetic code has acted as a catalyst for innovative technological developments that have been vital in the identification of genes associated with disease pathologies. This has allowed for the development of novel genetic therapies to treat a wide range of inherited disorders.
The new genomic era heralds earlier diagnoses, greatly improved prevention and treatment of diseases and enhanced avoidance of side effects from drugs.
Now, the latest information and findings that have an impact on the understanding and management of human health and disease will be available online to physicians around the globe with the launch of BioMed Central's premier medical journal Genome Medicine.
Today, Genome Medicine, an online peer-reviewed open access research journal will be launched at a special event at the 58th annual meeting of the American Society of Human Genetics (ASHG), in Philadelphia.
The launch issue is sponsored by Agilent, the electronic and bio-analytical measurement company. In addition to publishing high-quality research, Genome Medicine serves the international research community as a forum for the discussion and critical review of information about all areas of medicine informed by genomic research.
Genome Medicine will focus on the following areas:
Speaking of his support for the new journal, Charles Auffray of the Functional Genomics and Systems Biology for Health, Centre National de la Recherche Scientifique (CNRS), France and Section Editor said, "High-throughput experimental and computational technologies are revolutionizing our understanding of life by enabling global systems approaches beyond classical analytical molecular and cellular biology. Genome Medicine is a timely initiative to foster this transition from the highly fragmented scientific and medical landscape to the integrative systems biology and medicine which are needed to translate fundamental discoveries into useful healthcare services for the benefit of individual patients worldwide."
|Contact: Matt McKay|